V.VRS: New Gold Standard for Melanoma Screening?
Based on preliminary trial data, high throughput and other advantages, Verisante‟s Aura could eventually become the new gold-standard for skin cancer diagnosis. We look for Aura to launch in Europe/Canada/Australia by early 2012 and in the U.S. in late 2013. The size and high incidence of skin cancer in these markets, combined with Verisante‟s razor / razor blade business model and low cost base means revenue and earnings could ramp very quickly.
Full analyses of a large clinical trial is expected by May 2011, at which time probability of approval and launch timelines should be more clear. We are initiating on Verisante Technology, Inc. with an Outperform rating and $2.10 price target.
http://verisante.com/docs/verisante_zacks.pdf
